@Article{,
AUTHOR = {Vito Lampasona, Jordi Rio, Diego Franciotta, Roberto Furlan, Carlo Avolio, Raffaella Fazio, Vito Lavolpe, Angela Vincent, Giancarlo Comi, Maria Trojano, Xavier Montalban, Gianvito Martino},
TITLE = {Serial immunoprecipitation assays for interferon – (IFN)-β antibodies in multiple sclerosis patients},
JOURNAL = {European Cytokine Network},
VOLUME = {14},
YEAR = {2003},
NUMBER = {3},
PAGES = {154--157},
URL = {http://www.techscience.com/ECN/v14n3/66531},
ISSN = {1952-4005},
ABSTRACT = {We devised a sensitive, radioimmunoprecipitation assay (RIPA) for anti-interferon (IFN)-
b – binding antibody (BAB) detection. Our RIPA showed good agreement with a reference RIPA (mean
difference, – 3.2 ± 10.6 AU), and detected BAB to both IFN-β-1α and IFN-β-1β. Neutralizing antibodies to IFN-β
(NAB) were also determined with a standard method. BAB and NAB were measured in 393 serum samples from
77 multiple sclerosis (MS) patients treated with IFN-β-1α or -1β, who were studied over two years, and
subsequently classified as responders and non-responders. BAB were found at higher concentrations, and more
frequently detected, in IFN-β-1β- than in IFN-β-1α-treated patients, and, at highest titres, preferentially in
patients who were positive for NAB. However, in our series of MS patients, both titres and frequency of detection
of BAB or NAB did not differ between IFN-β responders and non-responders.},
DOI = {}
}